Shelley Force Aldred, Ph.D.
Co-founder, CEO
Shelley Force Aldred is CEO and co-founder of Rondo Therapeutics, a biopharmaceutical company developing bispecific therapeutic antibodies to fight cancer. In addition, Dr. Force Aldred is an adviser for Stanford’s SPARK translational medicine program and serves on the Board of Governors for the Stanford Medicine Alumni Association. Previously, Dr. Force Aldred served for 4 years as VP for Preclinical Development at Teneobio, a highly successful multispecific therapeutic antibody company. She was part of the formation of Teneobio and led the preclinical efforts creating a CD3xBCMA bispecific antibody, from product concept to IND-ready package. Dr. Force Aldred was formerly director of worldwide R&D for Active Motif following the acquisition of SwitchGear Genomics in 2013. In 2006, she co-founded SwitchGear Genomics, a venture-backed functional genomics platform company, and she served as its COO and Board Member. Prior to founding SwitchGear Genomics, Dr. Force Aldred was a Scientific Director on Stanford’s ENCODE Project and received her Ph.D. from Stanford University. She is an inventor on over 15 patents and an author on over 20 peer-reviewed scientific publications.
Nathan Trinklein, Ph.D.
Co-founder, CSO
Nathan is a co-founder of Rondo Therapeutics and currently serves as President and CSO. Prior to starting Rondo, Nathan was Chief Technology Officer at Teneobio where he played a key role in starting the company and led the team that was responsible for lead discovery, lead optimization, and development of the T-cell engager platform that was acquired in 2021. Prior to Teneobio, Nathan was a co-founder and CEO of SwitchGear Genomics, a venture-backed HTS platform company that was acquired in 2013. Earlier in his career, Nathan served as the Technical Director of the Stanford ENCODE project and received his Ph.D from Stanford University. Nathan also serves on the Board of Governors for the Stanford Medicine Alumni Association. Nathan has published over 30 peer-reviewed papers and is an inventor on over 15 patents.
Investors
Interested in joining our team?